Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. - Wu X; Devine SM; Go M; Nguyen JV; Lu BGC; Loi K; Kuchel NW; Lowes KN; Mitchell JP; Lessene G; Komander D; Call ME; et al. (PLoS pathogens, 2025)